entolimod
Small moleculeexperimental
Entolimod (CBLB502) is being developed by Cleveland Biolabs, Inc. for dual indications under the U.S. Food & Drug Administration's (FDA) animal efficacy rule as a pivotal-stage radiation countermeasure, and under the FDA's traditional drug approval pathway as a cancer treatment. — Wikipedia
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01527136)
Timeline
Indications
Mechanism of action
- Toll-like receptor 5AGONIST
TLR5 agonist
Binds to and activates TLR5 thereby stimulating tumor necrosis factor production and activating nuclear factor kappa B (NF-kB).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEntolimod ↗
- ChEMBLCHEMBL2108683 ↗
Also known as
- cblb502
- cblb502
- entolimod
- entolimod
- entolimod
- entolimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04176133 | Phase 2 | Oct 30, 2019 | Genome Protection, Inc, Mayo Clinic |
| NCT02715882 | Phase 2 | Nov 1, 2015 | BioLab 612 LLC, Cleveland BioLabs, Federal State Institution of Health of the Yaroslav Region Regional Clinical Oncology Hospital, Government of Russia |
| NCT01728480 | Phase 1 | Jan 1, 2014 | Cleveland BioLabs, National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01527136 | Phase 1 | Jan 1, 2012 | Cleveland BioLabs, National Cancer Institute (NCI), State University of New York, Buffalo |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cleveland BioLabs | For profit | 3 | 0 | 2 | 2012 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2012 |
| State University of New York, Buffalo | Academic/Hospital | 2 | 2 | 1 | 2012 |
| BioLab 612 LLC | For profit | 1 | 1 | 1 | 2015 |
| Federal State Institution of Health of the Yaroslav Region Regional Clinical Oncology Hospital | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Genome Protection, Inc | For profit | 1 | 0 | 1 | 2019 |
| Government of Russia | Government | 1 | 0 | 1 | 2015 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2019 |
8 organizations
Page 1 / 1